

**Contact:**

Loraine V. Upham

[Lori@CureDM.com](mailto:Lori@CureDM.com)

(505-515-1947)

## CureDM Completes Phase 1a Safety Study

Wilmington, DE – December 20, 2012 – CureDM announces the successful completion of Phase 1a clinical trial in healthy volunteers. This trial, characterized as a ‘Single Dose Escalation’ study, was carried out in cohorts of 8 subjects each e.g. 4 on drug and 4 on placebo and then repeated with the next higher dose. This dose escalation then continued until subsequent doses are limited either by the amount drug that can realistically be injected or side effects occur that limit further dosing. “We are pleased to report that this Phase 1a clinical trial has now been successfully completed without any noticeable side effects being observed.” Explained CEO, H. Joseph Reiser. The highest dose was achieved and increasing blood levels were recorded with each dose, roughly corresponding to the multiple of the dose being administered. Results will be submitted to the U.S. Food and Drug Administration for approval to begin a phase 1b trial in type 2 diabetes patients. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications will be pursued.

**About CureDM**

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit [www.curedm.com](http://www.curedm.com).

XXXXXX